en · de · es · fr · pt
sr9009-notes.peptides6155.com › News › Background And Research Status — Deep Dive

Background And Research Status — Deep Dive

By Editorial Desk · published 2025-06-29 · last reviewed 2025-08-07 · News

This is a working overview of certificate of analysis, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2025-08-07. Anything still debated is marked as such rather than presented as settled.

Background and Research Status

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

Analytical Detection and Regulatory Status

Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.

Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.

Sr9009 at a glance

PropertyValueNotes
Common nameSR9009Also referred to as Stenabolic in non-scientific contexts.
Chemical classSynthetic small moleculeNot a steroid or peptide hormone.
Receptor targetREV-ERBα and REV-ERBβNuclear receptor agonist in preclinical studies.
Development statusInvestigationalNo approved human therapeutic indication.
Regulatory attentionProhibited in sportListed by anti-doping authorities.

Analytical Detection and Stability

Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.

Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.

Related pages on this site

Background and Pharmacological Mechanism

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Background and Mechanism

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

Identity, Handling, and Regulation

Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Supporting material

In 2007, videos were shared on YouTube of alleged salvia users laughing uncontrollably, apparently unable to perform simple tasks or to communicate. In an interview published in the San Francisco Chronicle in June 2007, Daniel Siebert said that the videos "make salvia look like some horrible drug that makes people nuts and dangerous ..." and that it stops people from realizing "there are sensible ways to use something like this." Waco Representative Charles Anderson (R), who is sponsoring one of several bills to ban salvia in Texas, told colleagues at a legislative hearing about a video that depicts a salvia user behind the wheel of a car. "What we really worry about, is youngsters doing this and then getting in a vehicle or getting on a motorcycle or jumping in a pool somewhere." Michigan Representative Michael Sak (D) submitted a bill which proposed Schedule I classification of Salvia divinorum and salvinorin A. He said that if people had questions about the deleterious effects of salvia, they should go on YouTube to watch the videos. A reporter questioned Sak as to whether he had ever seen a "Girls Gone Wild" video, and whether that would incite him to make alcohol illegal (Sak replied that he hadn't yet had a chance to review the material).

==== Solvent casting and particulate leaching ==== Solvent casting and particulate leaching (SCPL) allows for the preparation of structures with regular porosity, but with limited thickness. First, the polymer is dissolved into a suitable organic solvent (e.g. polylactic acid could be dissolved into dichloromethane), then the solution is cast into a mold filled with porogen particles. Such porogen can be an inorganic salt like sodium chloride, crystals of saccharose, and gelatin or paraffin spheres. The size of the porogen particles will affect the size of the scaffold pores, while the polymer to porogen ratio is directly correlated to the amount of porosity of the final structure. After the polymer solution has been cast the solvent is allowed to fully evaporate, then the composite structure in the mold is immersed in a bath of a liquid suitable for dissolving the porogen: water in the case of sodium chloride, saccharose and gelatin or an aliphatic solvent like hexane for use with paraffin. Once the porogen has been fully dissolved, a porous structure is obtained. Other than the small thickness range that can be obtained, another drawback of SCPL lies in its use of organic solvents which must be fully removed to avoid any possible damage to the cells seeded on the scaffold.

Mergny and Lacroix determined that the addition of a bulky methyl group had a destabilizing effect on the i-motif formation when they compared phosphorothioate, the natural phosphodiester, methylphosphonate, and peptide linkages and determined that only phosphodiester and phosphorothioate oligodeoxynucleotides were capable of forming stable i-motifs.

=== Oceania === The white shark population is estimated to be 2,500–6,750 individuals around eastern Australia and New Zealand. In 1999, the Australian Government gave legal protection to the species under the Environmental Protection and Biodiversity Conservation (EPBC) Act, subsequently declaring it vulnerable in 2000. Similar protections exist at the state level—some predating federal law—with New South Wales, Tasmania, and Western Australia listing the species as vulnerable, and Victoria classifying it as endangered. To bolster these protections, the federal government launched the White Shark Recovery Plan in 2002 to mandate conservation research and regulate shark-related trade and tourism. An updated 2013 recovery plan reported moderate success, with 14 of its 34 original objectives completed. A study in 2012 found that Australia's white shark population is separated by the Bass Strait into genetically distinct eastern and western populations, necessitating regionalized conservation strategies. Population declines prior to protection were driven by commercial and sport fishing, along with entanglement in beach protection netting. By 2013, incidental deaths from commercial and recreational fishing had decreased, yet the population had not fully recovered. Despite federal protections, white sharks are still killed in state-run "shark control" programs (shark culling) intended to reduce attacks. Queensland and New South Wales continue to use nets and traps, which contribute to declining numbers in eastern Australia.

== Political implications == Allenby and Garreau propose that the Great Chain of Being, as developed within medieval Christian thought, helped legitimize political hierarchy and discourage rebellion for centuries. Both Catholic and later Protestant rulers appealed to this worldview. For example, the Protestant King James I himself wrote, "The state of monarchy is the most supreme thing upon earth: for kings are not only God's Lieutenants upon earth, and sit upon God's throne, but even by God himself they are called Gods."

Sources: en.wikipedia.org

Notes from published material

In December 2024, Trump stated a further proposal for the United States to purchase Greenland from Denmark, describing "ownership" and control of the island as "an absolute necessity" for national security purposes. This builds upon a prior offer from Trump to buy Greenland during his first term, which the Danish Realm refused, causing him to cancel his August 2019 visit to Denmark. On January 7, 2025, Trump's son Donald Trump Jr. visited Greenland's capital city Nuuk alongside Charlie Kirk to hand out MAGA hats. At a press conference the following day, Trump refused to rule out military or economic force to take over Greenland or the Panama Canal. However, he did rule out military force in taking over Canada. On January 14, the Trump-affiliated Nelk Boys also visited Nuuk, handing out dollar bills to locals. On January 16, the CEOs of major Danish companies Novo Nordisk, Vestas and Carlsberg among others were assembled for a crisis meeting in the Ministry of State to discuss the situation. On the subsequent day, former chief executive Friis Arne Petersen in the Danish Ministry of Foreign Affairs described the situation as "historically unheard of", while Noa Redington, special adviser to former prime minister Helle Thorning-Schmidt, compared the international pressure on Denmark that during the 2005 Jyllands-Posten Muhammad cartoons controversy. On February 12, 2025, a bill was introduced in Congress to advance efforts to acquire Greenland and rename it Red, White, and Blueland.

U.S. Congress and its committees; U.S. Government Accountability Office National Academies of Sciences, Institute of Medicine Office of the Inspector General Office of Management and Budget (e.g., Program Assessment Rating Tool) Association for Assessment and Accreditation of Laboratory Animal Care International The Joint Commission Accreditation Council for Graduate Medical Education Accreditation Council for Continuing Medical Education Nuclear Regulatory Commission Occupational Safety & Health Administration Association for Accreditation of Human Research Protection Programs Nina F. Schor, M.D. is the Deputy Director for Intramural Research and heads the Office of Intramural Research (OIR). In this role, he is responsible for oversight and coordination of all intramural research, training and technology transfer activities.

=== Methyltransferases in the biosynthetic cluster === Bioinformatic analysis identified four methyltransferases within the cluster. Bioinformatics suggest that btmB, is an O-methyltransferase, while the other three, btmC, G and K, are radical S-adenosyl methionine (SAM) methyltransferases. The radical SAM methyltransferases are believed to β-methylate amino acid residues within the precursor peptide. btmC is believed to methylate phenylalanine, btmG is believed to methylate both valines, and btmK is believed to methylate proline based on gene deletion studies. The three putative radical SAM methyltransferases encoded within the pathway are interesting for both mechanistic and biosynthetic reasons. Radical SAM methyltransferases are likely to methylate substrates by an unusual mechanism. Biosynthetically, β-methylations of amino acids are highly unusual in natural products. Polytheonamide B, a peptide natural product produced by a marine symbiont, is the only other structurally characterized example of direct β-methylation of a peptide natural product. The proposed methyl transfer from a SAM-utilizing enzyme was supported by earlier feeding studies with labeled methionine; labeled methionine is used because methionine is converted into SAM within cells. Even further, this study used stereospecifically labeled methionine ([methyl-(2H-3H)]-(2S, methyl-R)-methionine) to show that methylation occurred with a net retention of stereochemistry at the methyl group. The author speculated that net retention indicated a radical mechanism with a B12 intermediate.

=== Serotonin syndrome === Citalopram should not be taken with St John's wort, tryptophan or 5-HTP as the resulting drug interaction could lead to serotonin syndrome. With St John's wort, this may be caused by compounds in the plant extract reducing the efficacy of the hepatic cytochrome P450 enzymes that process citalopram. Tryptophan and 5-HTP are precursors to serotonin. When taken with an SSRI, such as citalopram, this can lead to levels of serotonin that can be lethal. This may also be the case when SSRIs are taken with SRAs (serotonin releasing agents) such as in the case of MDMA. It is possible that SSRIs could reduce the effects associated with an SRA since SSRIs stop the reuptake of Serotonin by blocking SERT. This would allow less serotonin in and out of the transporters, thus decreasing the likelihood of neurotoxic effects. However, these concerns are still disputed as the exact pharmacodynamic effects of citalopram and MDMA have yet to be fully identified. Citalopram is contraindicated in individuals taking MAOIs, owing to a potential for serotonin syndrome.

Sources: en.wikipedia.org

Background from the literature

The National Association of State Mental Health Program Directors said that antipsychotics are not interchangeable, and it recommends including trying at least one weight-neutral treatment for those patients with potential metabolic issues. Subtle, long-lasting forms of akathisia are often overlooked or confused with post-psychotic depression, in particular when they lack the extrapyramidal aspect that psychiatrists have been taught to expect when looking for signs of akathisia. Adverse effect on cognitive function and increased risk of death in people with dementia along with worsening of symptoms has been described in the literature. Antipsychotics, due to acting as dopamine D2 receptor antagonists and thereby stimulating pituitary lactotrophs, may have a risk of prolactinoma with long-term use. This is also responsible for their induction of hyperprolactinemia (high prolactin levels).

=== Plant extracts === Most or all plants produce chemical insecticides to stop insects eating them. Extracts and purified chemicals from thousands of plants have been shown to be insecticidal, however only a few are used in agriculture. In the USA 13 are registered for use, in the EU 6. In Korea, where it is easier to register botanical pesticides, 38 are used. Most used are neem oil, chenopodium, pyrethrins, and azadirachtin. Many botanical insecticides used in past decades (e.g. rotenone, nicotine, ryanodine) have been banned because of their toxicity.

Political independence was not necessarily the foreordained outcome of the political turmoil in Spanish America. "There was little interest in outright independence." As historians R.A. Humphreys and John Lynch note, "it is all too easy to equate the forces of discontent or even the forces of change with the forces of revolution." Since "by definition, there was no history of independence until it happened," when Spanish American independence did occur, explanations for why it came about have been sought. The Spanish American Wars of Independence were essentially a power vacuum in the Spanish monarchy that resulting in a rupture that gave rise to new states.

Independent researchers estimate that between 300,000 and 500,000 civilians died during this period while the Bangladesh government puts the number of dead at three million, a figure now nearly universally regarded as excessively inflated. Some academics such as Rudolph Rummel and Rounaq Jahan say both sides committed genocide; others such as Richard Sisson and Leo E. Rose believe there was no genocide. In response to India's support for the insurgency in East Pakistan, preemptive strikes on India by Pakistan's air force, navy, and marines sparked a conventional war in 1971 that resulted in an Indian victory and East Pakistan gaining independence as Bangladesh. Yahya Khan was replaced by Zulfikar Ali Bhutto as president; the country worked towards promulgating its constitution and putting the country on the road to democracy. In 1972 Pakistan embarked on an ambitious plan to develop its nuclear deterrence capability with the goal of preventing any foreign invasion; the country's first nuclear power plant was inaugurated in that same year. India's first nuclear test in 1974 gave Pakistan additional justification to accelerate its nuclear program. Democracy ended with a military coup in 1977 against the leftist PPP, which saw General Zia-ul-Haq become the president in 1978. From 1977 to 1988, President Zia's corporatisation and economic Islamisation initiatives led to Pakistan becoming one of the fastest-growing economies in South Asia.

== Male early puberty == Bicalutamide is used in combination with an aromatase inhibitor such as anastrozole or letrozole in the treatment of peripheral precocious puberty in young boys. The combination has specifically been used to treat male peripheral precocious puberty due to familial male-limited precocious puberty (FMPP, otherwise known as testotoxicosis) and, to a lesser extent, McCune–Albright syndrome. Whereas antigonadotropic medications such as GnRH modulators and progestogens like cyproterone acetate and medroxyprogesterone acetate are normally used to treat central precocious puberty, these medications are less or not at all effective in peripheral precocious puberty, as this type of precocious puberty is independent of gonadotropin secretion. Instead, androgens and estrogens must be more directly inhibited in peripheral precocious puberty via the use of sex-hormone receptor antagonists and synthesis inhibitors. A dosage of bicalutamide of 2 mg/kg (or about 40 to 60 mg in boys that are 20 to 30 kg or 45 to 65 lbs) once daily is recommended for use in male peripheral precocious puberty. Bicalutamide is used to block the actions of androgens in the condition, while the aromatase inhibitor is used to decrease levels of estrogens. The goal of treatment is to prevent further development of secondary sexual characteristics, and particularly to slow the rate of growth and improve final adult height. Due to the rare nature of peripheral precocious puberty, medications used in the treatment of the condition have only been studied limitedly in small numbers of patients.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.

Is SR9009 a steroid?

No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.

Has SR9009 been tested in humans?

Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.

Is SR9009 approved for human use?

No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.

Network